Salvacyl, known generically as triptorelin, is a type of medication that falls under the category of gonadotropin-releasing hormone (GnRH) agonists. It is primarily used in the management of advanced prostate cancer in men by reducing the levels of testosterone, which is known to fuel the growth of prostate cancer cells. Salvacyl works by initially increasing the release of certain hormones from the pituitary gland, but then it leads to a significant decrease in these hormone levels due to the downregulation of GnRH receptors. This process effectively lowers the production of testosterone. In addition to its use in prostate cancer, triptorelin may also be prescribed for conditions like endometriosis and uterine fibroids in women, as well as early puberty in children, by similarly regulating hormone levels. The medication is typically administered via injection by a healthcare professional.